nach oben

Breast Cancer Research and Treatment

Erschienen in:

24.02.2017 | Preclinical study

Co-targeting the HER and IGF/insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease

verfasst von: Ashok Chakraborty, Christos Hatzis, Michael P. DiGiovanna

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Interactions between HER2, estrogen receptor (ER), and insulin-like growth factor I receptor (IGF1R) are implicated in resistance to monotherapies targeting these receptors. We have previously shown in pre-clinical studies synergistic anti-tumor effects for co-targeting each pairwise combination of HER2, IGF1R, and ER. Strikingly, synergy for HER2/IGF1R targeting occurred not only in a HER2+ model, but also in a HER2-normal model. The purpose of the current study was therefore to determine the generalizability of synergistic anti-tumor effects of co-targeting HER2/IGF1R, the anti-tumor activity of triple-targeting HER2/IGF1R/ER in hormone-dependent cell lines, and the effect of using the multi-targeting drugs neratinib (pan-HER) and BMS-754807 (dual IGF1R/insulin receptor).

Methods

Proliferation and apoptosis assays were performed in a large panel of cell lines representing varying receptor expression levels. Mechanistic effects were studied using phospho-protein immunoblotting. Analyses of drug interaction effects were performed using linear mixed-effects regression models.

Results

Enhanced anti-proliferative effects of HER/IGF-insulin co-targeting were seen in most, though not all, cell lines, including HER2-normal lines. For ER+ lines, triple targeting with inclusion of anti-estrogen generally resulted in the greatest anti-tumor effects. Double or triple targeting generally resulted in marked increases in apoptosis in the sensitive lines. Mechanistic studies demonstrated that the synergy between drugs was correlated with maximal inhibition of Akt and ERK pathway signaling.

Conclusions

Dual HER/IGF-insulin targeting, and triple targeting with inclusion of anti-estrogen drugs, shows striking anti-tumor activity across breast cancer types, and drugs with broader receptor specificity may be more effective than single receptor selective drugs, particularly for ER− cells.

Ma CX, Reinert T, Chmielewska I, Ellis MJ (2015) Mechanisms of aromatase inhibitor reistance. Nat Rev Cancer 15:261–275CrossRefPubMed

Argiris A, Wang C-X, Whalen SG, DiGiovanna MP (2004) Synergistic interactions between tamoxifen and trastuzumab (Herceptin). Clin Cancer Res 10:1409–1420CrossRefPubMed

Chakraborty AK, Mehra R, DiGiovanna MP (2015) Co-targeting ER and HER family receptors induces apoptosis in HER2-normal or overexpressing breast cancer models. Anticancer Res 35:1243–1250PubMed

Scaltriti M, Rojo F, Ocaña A, Anido J, Guzman M, Cortes J, DiCosimo S, Matias-Guiu X, Ramon Y, Cajal S, Arriba J et al (2007) Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99(8):628–638CrossRefPubMed

Christianson TA, Doherty JK, Lin YJ, Ramsey EE, Holmes R, Keenan EJ, Clinton GM (1998) NH₂-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res 58:5123–5129PubMed

Berns K, Horlings HM, Hennessey BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzelez-Angulo AM, Stemke-Hale K, Hauptmann M et al (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12(4):395–402CrossRefPubMed

Chakrabarty A, Rexer BN, Wang SE, Cook RS, Engelman JA, Arteaga CL (2010) H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Oncogene 29(37):5193–5203CrossRefPubMedPubMedCentral

Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, Narasanna A, Chakrabarty A, Hilsenbeck SG, Huang J et al (2011) Loss of phasphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 29(2):166–173CrossRefPubMed

Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, Aysegul SA, Hortobagyi GN, Yu D (2010) PTEN, PIK3CA, p-AKT, and p-p70S6K status—Association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 177(4):1647–1656CrossRefPubMedPubMedCentral

10.

Majewski IJ, Nuciforo P, Mittempergher L, Bosma AJ, Eidtmann H, Holmes E, Sotiriou C, Fumagalli D, Jimenez J, Aura C et al (2015) PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. J Clin Oncol 56:2439

11.

Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP et al (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6(2):117–127CrossRefPubMed

12.

Nagy P, Friedländer E, Tanner M, Kapanen AI, Carraway KL, Isola J, Jovin TM (2005) Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 65(2):473–482PubMed

13.

Price-Schiavi SA, Jepson S, Li P, Arango M, Rudland PS, Yee L, Carraway KL (2002) Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer 99(6):783–791CrossRefPubMed

14.

Mitra D, Brumlik M, Okamgba S, Zhu Y, Duplessis T, Parvani J, Lesko S, Brogi E, Jones F (2009) An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol Cancer Ther 8(8):2152–2162CrossRefPubMed

15.

Rexer BN, Ham AJ, Rinehart C, Hill S, Granja-Ingram Nde M, Gonzålez-Angulo AM, Mills GB, Dave B, Chang JC, Liebler DC et al (2011) Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene 30(40):4163–4174CrossRefPubMedPubMedCentral

16.

Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW, Xiong Y, Tseng LM, Li SH, Ding Z et al (2011) Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 17(4):461–469CrossRefPubMed

17.

Kwong KY, Hung MC (1998) Identification of a novel alternative splicing form of human HER2/neu proto-oncogene (ABSTRACT). Proc Am Assoc Cancer Res 39:205

18.

Diermeier S, Horváth G, Knuechel-Clarke R, Hofstaedter F, Szöllösi J, Brockhoff G (2005) Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res 304:604–619CrossRefPubMed

19.

Motoyama AB, Hynes NE, Lane HA (2002) The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 62(11):3151–3158PubMed

20.

Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM (2007) Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445(7126):437–441CrossRefPubMedPubMedCentral

21.

Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827):1039–1043CrossRefPubMed

22.

Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski B-A et al (2007) Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 13(4):1198–1207CrossRefPubMed

23.

Huang X, Gao L, Wang S, McManaman JL, Thor AD, Yang X, Esteva FJ, Liu B (2010) Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-I receptor in breast cancer cells resistant to Herceptin. Cancer Res 70(3):1204–1214CrossRefPubMed

24.

Lu YH, Zi XL, Zhao YH, Mascarenhas D, Pollak M (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93(4):1852–1857CrossRefPubMed

25.

Nahta R, Yuan LX, Du Y, Esteva FJ (2007) Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther 6(2):667–674CrossRefPubMed

26.

Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, Paulazzo G, Lyass L, Trusk P, Hill J et al (2006) A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci USA 103(20):7795–7800CrossRefPubMedPubMedCentral

27.

Wang Y-C, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, Botero MF, Healy NA, Hilsenbeck SG, Phillips GL et al (2011) Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers—role of estrogen receptor and HER2 reactivation. Breast Cancer Res 13(R121):1–19CrossRef

28.

Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A et al (2009) Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 27(33):5529–5537CrossRefPubMed

29.

Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ et al (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27(33):5538–5546CrossRefPubMed

30.

Burstein HJ, Cirrincione CT, Barry WT, Chew HK, Tolaney SM, Lake DE, Ma C, Blackwell KL, Winer EP, Hudis CA (2014) endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer—CALGB 40302 (Alliance). J Clin Oncol 32(35):3959–3966CrossRefPubMedPubMedCentral

31.

Nahta R, Huan LXH, Zhang B, Kobayashi R, Esteva FJ (2005) Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65(23):11118–11128CrossRefPubMed

32.

Fox EM, Miller TW, Balko JM, Kuba MG, Sánchez V, Smith RA, Liu S, González-Angulo AM, Mills GB, Ye F et al (2011) A kinome-wide screen identifies the Insulin/IGF-1 receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res 71(21):6773–6784CrossRefPubMedPubMedCentral

33.

Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H et al (1995) Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491–1494CrossRefPubMed

34.

Lee AV, Weng CN, Jackson JG, Yee D (1997) Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol 152(1):39–47CrossRefPubMed

35.

Martin MB, Franke TF, Stoica GE, Chambon P, Katzenellenbogen BS, Stoica BA, McLemore MS, Olivo SE, Stoica A (2000) A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology 141(12):4503–4511PubMed

36.

Jones HE, Goddard L, Gee JMW, Hiscox S, Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE, Nicholson RI (2004) Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 11(4):793–814CrossRefPubMed

37.

Balañá ME, Labriola L, Salatino M, Movsichoff F, Peters G, Charreau EH, Elizalde PV (2001) Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells. Oncogene 19(1):34–47CrossRef

38.

Camirand A, Lu Y, Pollak M (2002) Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med Sci Monit 8(12):BR521–BR526PubMed

39.

Fürsenberger G, Morant R, Senn HJ (2003) Insulin-like growth factors and breast cancer. Onkologie 26:290–294

40.

Huynh H, Nickerson T, Pollak M, Yang X (1996) Regulation of insulin-like growth factor I receptor expression by the pure antiestrogen ICI 182780. Clin Cancer Res 2(12):2037–2042PubMed

41.

Kahlert S, Neudling S, van Eickels M, Vetter H, Meyer R, Grohe C (2000) Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J Biol Chem 275(24):18447–18453CrossRefPubMed

42.

Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK, Yee D (1999) Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol 13(5):787–796CrossRefPubMed

43.

Happerfield LC, Miles DW, Barnes DM, Thomsen LL, Smith P, Hanby A (1997) The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue. J Pathol 183(4):412–417CrossRefPubMed

44.

Santen RJ, Jeng MH, Wang JP, Song R, Masamura S, McPherson R, Santner S, Yue W, Shim WS (2001) Adaptive hypersensivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. J Steroid Biochem Mol Biol 79((1–5 Speciall Issue SI)):115–125CrossRefPubMed

45.

Song RX, Barnes CJ, Zhang ZG, Bao YD, Kumar R, Santen RJ (2004) The role of Shc and insulin-like growth factor I receptor in mediating the translocation of estrogen receptor a to the plasma membrane. Proc Natl Acad Sci USA 101(7):2076–2081CrossRefPubMedPubMedCentral

46.

Song RX, Santen RJ, Kumar R, Adam L, Jeng MH, Masamura S, Yue W (2002) Adaptive mechanisms induced by long-term estrogen deprivation in breast cancer cells. Mol Cell Endocrinol 193(1–2 Special Issue SI):29–42CrossRefPubMed

47.

Song RXD, McPherson RA, Adam L, Bao YD, Shupnik M, Kumar R, Santen RJ (2002) Linkage of rapid estrogen action to MAPK activation by ER alpha-Shc association and Shc pathway activation. Mol Endocrinol 16(1):116–127PubMed

48.

Zhang ZG, Maier B, Santen RJ, Song RXD (2002) Membrane association of estrogen receptor alpha mediates estrogen effect on MAPK activatioin. Biochem Biophys Res Commun 294(5):926–933CrossRefPubMed

49.

Razandi M, Pedram A, Park ST, Levin ER (2003) Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem 278(4):2701–2712CrossRefPubMed

50.

Chakraborty AK, Liang K, DiGiovanna MP (2008) Co-targeting insulin-like growth factor I receptor and HER2: Dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer. Cancer Res 68(5):1538–1545CrossRefPubMed

51.

Wang C-X, Koay DC, Edwards A, Lu Z, Mor G, Ocal IT, DiGiovanna MP (2005) In vitro and in vivo effects of combination of trastuzumab (Herceptin) and tamoxifen in breast cancer. Breast Cancer Res Treat 92(3):251–263CrossRefPubMed

52.

Chakraborty AK, Welsh A, DiGiovanna MP (2010) Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines. Breast Cancer Res Treat 120:327–335CrossRefPubMed

53.

Kaufman PA, Ferrero JM, Bourgeois H, Kennecke H, DeBoer R, Jacot W, McGreivy J, Suzuki S, Loh E, Robertson J (2010) A ramdomized, double-blind, placebo-controlled, phase 2 study of AMG 479 with exemestane (E) or fulvestrant (F) in postmenopausal women with hormone-receptor positive (HR+) metastatic (M) or locally advanced (LA) breast cancer (BC). Cancer Res 70(24):76s (ABSTRACT S71–74)

54.

Robertson JFR, Ferrero J-M, Bourgeois H, Kennecke H, de Boer RH, Jacot W, McGreivy J, Suzuki S, Zhu M, McCaffery I et al (2013) Ganitumab with either exemestane or fulvestrant fo postmenopausal women with advanced, hormonereceptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. Lancet Oncol 14:228–235CrossRefPubMed

55.

Haluska P, Bernath AM, Ballman KV, Dueck AC, Linden HM, Goetz MP, Northfelt DW, Hou X, Tenner KS, Tienchaiananda P et al (2014) Randomized phase II trial of capecitabine and lapatinib with or without cixutumumab in patients with HER2+ breast cancer previously treated with trastuzumab and an anthracycline and/or a taxane: NCCTG N0733 (Alliance). J Clin Oncol 32(supplement(5s)):Abstract 632

56.

Buck E, Gokhale PC, Koujak S, Brown E, Eyzaguirre A, Tao N, Rosenfeld-Franklin M, Lerner L, Chiu MI, Wild R et al (2010) Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): Rationale for cotargeting IGF-1R and IR in cancer. Mol Cancer Ther 9(10):2652–2664CrossRefPubMed

57.

R: A language and environment for statistical computing [http://www.R-project.org/]

58.

Bates D, Mächler M, Bolker BM, Walker SC (2015) Fitting linear mixed-effects models using lme4. J Stat Softw 67(1):1–48CrossRef

59.

Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F et al (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10(6):515–527CrossRefPubMedPubMedCentral

60.

Riedemann J, Takiguchi M, Sohall M, Macaulay VM (2007) The EGF receptor interacts with the type 1 IGF receptor and regulates its stability. Biochem Biophys Res Commun 355(3):707–714CrossRefPubMed

61.

Canonici A, Gijsen M, Mullooly M, Bennett R, Bouguern N, Pedersen K, O’Brien NA, Roxanis I, Li J-L, Bridge E et al (2013) Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget 4(10):1592–1605CrossRefPubMedPubMedCentral

62.

Wissner A, Mansour TS (2008) The development of HKI-272 and related compounds for the treatment of cancer. Arch Pharm Chem Life Sci 341:465–477CrossRef

63.

Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, Wang F, Gualberto A, Beebe JS et al (2005) Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11:2063–2073CrossRefPubMed

64.

Browne BC, Eustace AJ, Kennedy S, O’Brien NA, Pedersen K, McDermott MSJ, Larkin A, Ballot J, Mahgoub T, Sclafani F et al (2012) Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours. Breast Cancer Res Treat 137:717–727CrossRef

65.

Hou X, Huang F, Macedo LF, Harrington SC, Reeves KA, Greer A, Finckenstein FG, Brodie A, Gottardis MM, Carboni JM et al (2011) Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer. Cancer Res 71(24):7597–7607CrossRefPubMedPubMedCentral

Titel: Co-targeting the HER and IGF/insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease
verfasst von: Ashok Chakraborty
Christos Hatzis
Michael P. DiGiovanna
Publikationsdatum: 24.02.2017
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2017
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-017-4169-9

Springer Medizin

Co-targeting the HER and IGF/insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients

Swedish prospective multicenter trial on the accuracy and clinical relevance of sentinel lymph node biopsy before neoadjuvant systemic therapy in breast cancer

High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function

Characteristics of BRCA1/2 mutations carriers including large genomic rearrangements in high risk breast cancer patients

The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancer

The influences of peritumoral lymphatic invasion and vascular invasion on the survival and recurrence according to the molecular subtypes of breast cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie